Connect with:
Monday / January 13. 2025

logo
mobile-logo
HomePosts Tagged "Indian Immunologicals Limited"
Acquaculture, AgroPolicy, Animal Health, Animal Husbandry, Dairy, India, Live Stock

 Clonclave focus on enhancing vaccination programs, improving livestock health, building resilient supply chains for pandemic preparedness, strengthening pandemic responses and advancing disease surveillance.

The Department of Animal Husbandry and Dairying under the Ministry of Fisheries, Animal Husbandry and Dairying in collaboration with Indian Immunologicals Limited and National Dairy Development Board (NDDB) organised a “Conclave on Pandemic Preparedness & Vaccine Innovation” in Hyderabad on 10th January 2025.

The conclave was inaugurated by Prof. Dr Vinod K Paul, Member-Health, NITI AAYOG as the Chief Guest. Speaking on the occasion he emphasised the need to bolster veterinary infrastructure to effectively address future pandemics. This includes enhancing diagnostic facilities to ensure early detection and rapid response to emerging diseases. He also underscored the importance of establishing advanced platforms for the development and production of next-generation animal vaccines, which are crucial for preventing the spillover of zoonotic diseases and safeguarding both animal and human health. He said that strengthening these critical components aligns with the broader goal of building a resilient healthcare framework under the One Health approach.

Alka Upadhyaya, Secretary, Department of Animal Husbandry and Dairying, stated that the Government needs to spend more on animal health for better productivity and also improve supply chain and cold chain systems to make the last mile delivery effective.

Dr Abhijit Mitra, Animal Husbandry Commissioner, in his address emphasised upon the need to ensure vaccine security and pre-qualifications for animal vaccines.

The Conclave aimed to foster a deeper understanding of various aspects of “One Health,” focusing on enhancing vaccination programs, improving livestock health, building resilient supply chains for pandemic preparedness, strengthening pandemic responses, advancing disease surveillance, and streamlining vaccine testing, fostering artificial intelligence in healthcare, cell and gene therapy vaccines and regulatory pathways for approval.

 Clonclave focus on enhancing vaccination programs, improving

Acquaculture, Agribusiness, Agro Universities, Agrotech, Animal Health, Collaborations, Company News, India, Live Stock

The VNN vaccine developed by CIBA can prevent vertical transmission of the disease to the offsprings and prevent mortality in fingerlings.

Indian Immunologicals Limited (IIL), a leading vaccine manufacturer, has announced partnership with Central Institute of Brackishwater Aquaculture (CIBA), Chennai, an Indian Council of Agricultural Research (ICAR) Institute for the commercial development of a recombinant monovalent viral nervous necrosis vaccine for finfish developed by CIBA.

IIL ventured into aqua business in October 2022 by launching products for aquaculture health market dealing with pond management and fish or shrimp gut management and subsequently announced commercial development of fish vaccines with ICAR’s CIFE, Mumbai and CIFA, Bhubaneswar. India is the 3rd largest fish producer in the global sphere and more than 65 per cent of India’s fish is through Inland Fisheries and Aquaculture. The main constraint to aquaculture globally, however, is disease with an estimate that 20 per cent of all cultured aquatic animals are lost because of infectious diseases, amounting to >10 billion USD in losses annually on a global scale.

Viral nervous necrosis (VNN) or viral encephalopathy and retinopathy (VER) is an acute viral disease affecting several species of marine, brackishwater and freshwater fishes. The disease causes up to 100 per cent mortality in larval and early juvenile stages. Adult fish when infected, is asymptomatic, but can transmit the virus to the offspring through eggs and gonadal fluids.

Speaking on the occasion, Dr K Anand Kumar, Managing Director, Indian Immunologicals Limited said, “IIL is the first in India to get to fish vaccines. We are covering different kind of fishes (fresh water, brackish water, etc.) and culture conditions (pond, cage culture, etc.) and are aware of the challenges associated with being the first, having been in similar situations for many other livestock vaccines. We are working at multiple fronts in defining pathways for commercial development of fish vaccines in India”.

Dr. Priyabrata Pattnaik, Deputy Managing Director, Indian Immunologicals Limited added “IIL as a leading “One Health” organization is committed to developing vaccines for different fish pathogens with a long-term strategic objective of reducing use of antibiotics in aquaculture there by antimicrobial resistance in environment”.

Dr. Kuldeep K. Lal, Director, ICAR-CIBA said “viral nervous necrosis is a major threat for brackishwater aquaculture. The VNN vaccine developed by CIBA can prevent vertical transmission of the disease to the offsprings and prevent mortality in fingerlings. The vaccine can play a significant role in controlling the loss due to VNN in India and other Asian countries”.

Aquaculture in India suffers economic losses due to infections caused by several bacterial, viral, fungal, and other aetiological agents. Currently these infections are being managed by anti-infectives and other conventional measures with varying degree of success. With the rising concern pertaining on anti-microbial resistance (AMR) and chemical free food products both at global and domestic platforms, there is a growing need for better control measures against these infections. Currently there is no fish vaccines available in India on a commercial scale to prevent aquaculture infections.

The VNN vaccine developed by CIBA can

Live Stock

The vaccine is expected to help control of Goat Pox disease in the country

Indian Immunologicals Limited (IIL), a leading vaccine manufacturer base out of Hyderabad, has launched ‘Goat Pox Vaccine (Raksha Goat Pox)’ for the significant Goat population in the country. Raksha Goat Pox vaccine is expected to help control of Goat Pox disease in the country, which has high economic importance among country’s rural livestock growers.

IIL’s Raksha Goat Pox vaccine is a live attenuated vaccine IP (Uttarkashi strain) grown on Vero Cell Culture. The Primary vaccination to be done at 3 months of age and revaccination annually with a dose rate of 1 ml, to be administered subcutaneously.  The technology for vaccine manufacturing and testing of Goat Pox Vaccine was obtained from Indian Council of Agriculture Research – Indian Veterinary Research Institute (ICAR- IVRI), Government of India and has been tested and certified by IVRI for commercial release.  

Speaking on the occasion from the launch, Managing Director of IIL, Dr K Anand Kumar said, “Indian Immunologicals is committed to introducing such products for the national interest and will abundantly help marginal livestock growers of their livelihood and protect their flock from various diseases“. Dr Priyabrata Pattnaik, Deputy Managing Director and Sobhan Babu, Vice President – Animal Health Trade of IIL were also present in the Goat Pox Vaccine launch event.

Earlier IIL launched several other vaccines such as Classical Swine Fever vaccine, PPR Vaccine etc under tech transfer arrangement with IVRI. 

The vaccine is expected to help control